DKK 371.15
Key Takeaways
Risk factor
Low default risk
Profitability factor
Very strong margins and returns
About
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV
Target Price
The average target price of NOVO-B.CO is 439 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
